Prochloramide is a new 1. 1 anti-prostate cancer drug developed by Suzhou Development Pharmaceutical Co., Ltd., which is a new compound optimized by computer design based on the core structure of the latest anti-prostate cancer drug enzarumide in the United States. Prochloramide has higher targeting activity than enzalutamide, and it is expected to be the best drug for the second generation of anti-prostate cancer clinical drugs targeting androgen receptors.
Extended data:
Research progress of propionamide
The clinical trial of Proch amine was conducted in China and the United States at the same time, and the clinical trial in China has entered the second phase.
Clinical data show that pramipexole has good safety and tolerance. Considering that the over-expression and mutation of AR is the main mechanism of drug resistance of prostate cancer cells to abiraterone/enzarulamine therapy, pucrulamine can overcome the drug resistance of prostate cancer cells to these drugs by down-regulating the expression of AR gene, which is expected to become a more effective and safer new generation AR antagonist for the treatment of castration-resistant prostate cancer. Once it is approved for marketing, it will have broad market prospects.
Cultivate the "Do not forget your initiative mind" in the pharmaceutical industry, pay attention to the quality of finished drugs, realize the idea of innovative drugs entering the market as soon as possible, concentrate on being practical and not arrogant. State support is the driving force, and patient satisfaction is the goal. The "Twelfth Five-Year Plan" has laid the foundation, and the "Thirteenth Five-Year Plan" will help the pharmaceutical industry to develop more steadily.
Sohu. Jointly develop a new anticancer drug, Procuramide.